Boundless Bio, Inc. (BOLD) company profile
Close on Nov 12, 2026Market cap $55.96MP/E –Yield –
About Boundless Bio
Pharmaceutical Preparations, SIC 2834
Boundless Bio is a clinical-stage oncology company developing extrachromosomal DNA directed therapeutics to treat oncogene amplified cancers. Using its proprietary Spyglass platform, the company identifies synthetic lethal targets essential for extrachromosomal DNA function and designs small molecule therapies to inhibit them. Its lead product candidate, BBI-940, is an oral selective degrader targeting a kinesin involved in DNA segregation during mitosis, which entered a Phase 1 clinical trial for patients with certain types of breast cancer.
The company operates in the United States and manages its primary business and clinical research activities from California. Its corporate headquarters and principal executive offices are located in San Diego, California.
Summary of the business section of Boundless Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Boundless Bio, Inc.
- Founded
- 2018
- Headquarters
- La Jolla, CA
- Address
- 11099 North Torrey Pines Road, Suite 150 92037
- Phone
- (858) 766-9912
- Website
- boundlessbio.com
- Employees
- 28, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Diego, CA
Stock & identifiers
- Ticker
- BOLD
- Exchange
- Nasdaq
- IPO date
- Mar 28, 2024
- Shares outstanding
- 23M, Aug 5, 2026
- Public float
- $18.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1782303
- CUSIP
- 10170A100
- ISIN
- US10170A1007
- FIGI
- BBG00Q4W34T4
- Share class FIGI
- BBG00Q4W34V1
- EIN
- 83-0751369
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Zachary Hornby | President & CEO, Director | 256,410 |
| Jessica Oien | See Remarks | – |
| Robert Doebele | Chief Medical Officer | – |
| David A. Hinkle | See Remarks | 100 |
| Christian Hassig | Chief Scientific Officer | 25,641 |
| Jennifer Lew | Director | – |
| Jonathan E. Lim | Director | 653,479 |
| James Christensen | Director | – |
| Nancy Whiting | Director | – |
| Christine Brennan | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Zachary D. Hornby President, Chief Executive Officer, and Director | $638.00K | $628.35K | $333.36K | $3.50K | $1.60M | -74% |
| Robert Doebele, M.D., Ph.D. Chief Medical Officer | $458.51K | $333.00K | $183.33K | $3.50K | $978.34K | – |
| Christian Hassig, Ph.D. Chief Scientific Officer | $478.30K | $202.35K | $191.20K | $3.50K | $875.35K | -59% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Mar 28, 2024
- Offer price
- $16.00
- Securities offered
- 6,250,000
- Gross proceeds
- $100.00M
- Exchange
- Nasdaq
- First trading day
- Mar 28, 2024
- First-day close
- $14.25-10.9%
- Lock-up ends (est.)
- Sep 24, 2024
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 8, 2026, we had 28 employees, all of whom are full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 8, 2026 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Mar 28, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 22, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?